Search hospitals > Nevada > Las Vegas

Summerlin Hospital Medical Center

Claim this profile
Las Vegas, Nevada 89144
Global Leader in Cancer
Global Leader in Tumors
Conducts research for Leukemia
Conducts research for Recurrence
Conducts research for Lymphoma
233 reported clinical trials
2 medical researchers
Photo of Summerlin Hospital Medical Center in Las VegasPhoto of Summerlin Hospital Medical Center in Las VegasPhoto of Summerlin Hospital Medical Center in Las Vegas

Summary

Summerlin Hospital Medical Center is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Tumors, Leukemia, Recurrence, Lymphoma and other specialties. Summerlin Hospital Medical Center is involved with conducting 233 clinical trials across 493 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.

Area of expertise

1Cancer
Global Leader
Summerlin Hospital Medical Center has run 90 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage I
2Tumors
Global Leader
Summerlin Hospital Medical Center has run 50 trials for Tumors. Some of their research focus areas include:
Stage IV
Stage I
Stage II

Top PIs

Clinical Trials running at Summerlin Hospital Medical Center

Breast Cancer
Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Osteosarcoma
Gastric Cancer
Tumors
Germ Cell Tumors
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Marker-Directed Monitoring

for Breast Cancer

This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Summerlin Hospital Medical Center?
Summerlin Hospital Medical Center is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Tumors, Leukemia, Recurrence, Lymphoma and other specialties. Summerlin Hospital Medical Center is involved with conducting 233 clinical trials across 493 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.